EVNIN LUKE sold $28K of HOWL (indirect holdings)
EVNIN LUKE sold 76,928 indirectly-held shares of Werewolf Therapeutics, Inc. (HOWL) at $0.37 on 2026-06-09 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure confirms an open-market sale by a director (indirect ownership) and provides the post-transaction share count; it does not include new operating or financial fundamentals.
Market read
For HOWL, this is a fresh insider-selling datapoint, but the 10b5-1 structure makes it less likely to drive a durable repricing by itself.
What to watch
Traders may watch for clustering of insider sales across multiple directors/officers or repeated Form 4 activity, which would be more informative than a single 10b5-1 sale.
Background
The article is an SEC Form 4 insider transaction disclosure for Werewolf Therapeutics, Inc.
Ticker impact
Werewolf Therapeutics director EVNIN LUKE sold 76,928 shares in an open-market transaction at $0.3700/share, per Form 4 filed June 10.
Low probability of sustained downside solely from this Form 4; any impact is likely short-lived unless follow-on selling appears.
The filing is a primary-source insider transaction, but it explicitly states a pre-arranged Rule 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.
Market effects
No broader sector read-through; this is company-specific insider activity.
None indicated.
None indicated.
Counterpoint
Because the sale is on a pre-arranged 10b5-1 schedule, it may reflect liquidity planning rather than bearish fundamentals.
Key entities
- issuerWerewolf Therapeutics, Inc.
Company whose director insider sale is disclosed on SEC Form 4.
- insiderEVNIN LUKE
Director who sold 76,928 shares at $0.3700/share under a Rule 10b5-1 plan.
